Biomolecules and Biomedicine
ISSN: 2831-0896 (Print) | ISSN: 2831-090X (Online)
Journal Impact Factor® (2025): 2.8
CiteScore® (2025): 4.7
www.biomolbiomed.com | blog.bjbms.org

SUPPLEMENTAL DATA

Moderate carpal tunnel syndrome: Factors associated with long-term surgery risk after corticosteroid injection

Meral Bilgilisoy Filiz[1*], Nur Altın[2], Muhammet Hüseyin Sarı[3], Hanife Hale Hekim[1], Ülkü Uçar[4], Tuncay Çakır[1], Şebnem Koldaş Doğan[1]

[1]Department of Physical Medicine and Rehabilitation, Antalya Training and Research Hospital, Health Sciences University, Antalya, Türkiye;
[2]Department of Physical Medicine and Rehabilitation, Denizli State Hospital, Denizli, Türkiye;
[3]Department of Physical Medicine and Rehabilitation, Kadirli State Hospital, Osmaniye, Türkiye;
[4]Department of Physical Medicine and Rehabilitation/Rheumatology, Faculty of Medicine, Akdeniz University, Antalya, Türkiye.
*Correspondence to **Meral Bilgilisoy Filiz**: mbilgilisoy@gmail.com.

Full article is available at the following link: Moderate carpal tunnel syndrome: Factors associated with long-term surgery risk after corticosteroid injection

Table S1. STROBE Statement—Checklist of items that should be included in reports of cohort studies

Section/topic	Item No	Recommendation	Reported on (section/location)
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title; Abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction, para 1–2
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction, final paragraph
Methods			
Study design	4	Present key elements of study design early in the paper	Methods, Study design and participants
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods, Study design and participants
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Methods, Study design and participants
		(b) For matched studies, give matching	Not applicable

		criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers; give diagnostic criteria, if applicable	Methods, Clinical evaluation / Electrophysiological and ultrasonographic assessment / Long-term follow-up and outcome definition
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement); describe comparability of assessment methods if more than one group	Methods, Clinical evaluation / Electrophysiological and ultrasonographic assessment
Bias	9	Describe any efforts to address potential sources of bias	Methods (interviewer blinding, e-health record verification); Limitations
Study size	10	Explain how the study size was arrived at	Methods, Study design and participants (derived from parent trial sample); Limitations
Quantitative variables	11	Explain how quantitative variables were handled in the analyses; if applicable, describe which groupings were chosen and why	Statistical analysis
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Statistical analysis
		(b) Describe any methods used to examine subgroups and	Statistical analysis

		interactions	
		(c) Explain how missing data were addressed	Statistical analysis
		(d) If applicable, explain how loss to follow-up was addressed	Results (Table 5); Limitations
		(e) Describe any sensitivity analyses	Statistical analysis (proportional hazards assumption check)
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Results, first paragraph; Figure 2
		(b) Give reasons for non-participation at each stage	Results, first paragraph; Figure 2
		(c) Consider use of a flow diagram	Figure 2
Descriptive data	14*	(a) Give characteristics of study participants and information on exposures and potential confounders	Table 1; Table 2
		(b) Indicate number of participants with missing data for each variable of interest	Statistical analysis (0% missing)
		(c) Summarise follow-up time (eg, average and total amount)	Results (median follow-up 55.2 months)
Outcome data	15*	Report numbers of	Results; Figure 1

		outcome events or summary measures over time	(Kaplan-Meier)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% CI)	Table 3; Table 4
		(b) Report category boundaries when continuous variables were categorized	Not applicable (variables analyzed continuously)
		(c) Translate estimates of relative risk into absolute risk for a meaningful time period, if relevant	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Statistical analysis / Results (correlation matrix, PH assumption)
Discussion			
Key results	18	Summarise key results with reference to study objectives	Discussion, first paragraph
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision; discuss both direction and magnitude of any potential bias	Limitations paragraph
Interpretation	20	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results	Discussion; Conclusion

		from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	Limitations; Conclusion
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding statement

*Provide information separately for exposed and unexposed groups where applicable. An explanation for each checklist item is available at www.strobe-statement.org. This checklist is best used in conjunction with the STROBE Explanation and Elaboration article. **Abbreviations**: CI, confidence interval; PH, proportional hazards; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.